Co<sup>60</sup> Vitamin B<sub>12</sub> Binding Capacity of Serum in Persons with Hematologic Disorders, Various Medical Diseases and Neoplasms

Meyer, Leo M.; Bertcher, Robert W.; Cronkite, Eugene P.; Suárez, Ramón M.; Miller, Inez F.; Mulzac, Claire W.; Olivarreta, Sara T.

doi:10.1111/j.0954-6820.1961.tb07866.x

Cited by 27 publications

(3 citation statements)

References 22 publications

(12 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Conversely labelled vitamin B12 bound to normal serum was cleared slowly from plasma of a patient with myeloid metaplasia. The mechanisms are undoubtedly different as increased binding capacity of serum in chronic myeloid leukaemia (untreated) and some cases of myeloid metaplasia but not pernicious anaemia has been demonstrated in this and other laboratories (Meyer et al 1961).…”

Section: Discussionmentioning

confidence: 66%

Co⁵⁷ Vitamin B₁₂ Clearance Studies in Pernicious Anaemia

Meyer

Osofsky

Miller

1967

Scandinavian Journal of Haematology

Self Cite

View full text Add to dashboard Cite

1) Clearance rate of intravenously administered radioactive vitamin B,, in untreated pernicious anaemia patients is slow in 50 per cent of cases studied.(2) Administration of labelled vitamin B,, bound to slow serum to 'normal clearing' pernicious anaemia subjects or to normal persons is followed by normal clearance rate.(3) Radioactive vitamin B,, bound to normal serum is cleared at a normal rate in pernicious anaemia patients with slow clearance rate. (4) Radioactive vitamin B,, bound to slow serum when mixed with normal serum in proportions of 1:l or 1 : O S is cleared at a normal rate in 'slow clearing' pernicious anaemia patients.( 5 ) These studies suggest the presence of a 'serum factor' in normal serum and some patients with pernicious anaemia in relapse which enhances clearance of vitamin B,, bound to 'slow serum'.

show abstract

Section: Discussionmentioning

confidence: 66%

Co⁵⁷ Vitamin B₁₂ Clearance Studies in Pernicious Anaemia

Meyer

Osofsky

Miller

1967

Scandinavian Journal of Haematology

Self Cite

View full text Add to dashboard Cite

show abstract

“…In addition to the high B12 needs and uptake by cancer cells, the link between cobalamin and neoplasms also involves B12-binding proteins, the transcobalamins. Before the identification of transcobalamins in the 1960s, it was demonstrated that the plasma cobalamin-binding capacity was raised in myeloid blood malignancies (not detailed in this review) and in solid cancers [ 6 , 7 ], paralleling the accumulation of a yet unknown cobalamin-binding protein [ 7 ]. A few years later, the identification and dosage of transcobalamins [ 8 , 9 ] led to the observation of high transcobalamin levels in solid cancers [ 10 , 11 , 12 ].…”

Section: Introductionmentioning

confidence: 99%

Diagnostic and Therapeutic Perspectives Associated to Cobalamin-Dependent Metabolism and Transcobalamins’ Synthesis in Solid Cancers

2022

View full text Add to dashboard Cite

Cobalamin or vitamin B12 (B12) is a cofactor for methionine synthase and methylmalonyl-CoA mutase, two enzymes implicated in key pathways for cell proliferation: methylation, purine synthesis, succinylation and ATP production. Ensuring these functions in cancer cells therefore requires important cobalamin needs and its uptake through the transcobalamin II receptor (TCII-R). Thus, both the TCII-R and the cobalamin-dependent metabolic pathways constitute promising therapeutic targets to inhibit cancer development. However, the link between cobalamin and solid cancers is not limited to cellular metabolism, as it also involves the circulating transcobalamins I and II (TCI or haptocorrin and TCII) carrier proteins, encoded by TCN1 and TCN2, respectively. In this respect, elevations of B12, TCI and TCII concentrations in plasma are associated with cancer onset and relapse, and with the presence of metastases and worse prognosis. In addition, TCN1 and TCN2 overexpressions are associated with chemoresistance and a proliferative phenotype, respectively. Here we review the involvement of cobalamin and transcobalamins in cancer diagnosis and prognosis, and as potential therapeutic targets. We further detail the relationship between cobalamin-dependent metabolic pathways in cancer cells and the transcobalamins’ abundancies in plasma and tumors, to ultimately hypothesize screening and therapeutic strategies linking these aspects.

show abstract

“…Active chronic myelocytic leukaemia is characterized by a high level of serum vitamin B,, (1, 5, 1 1 , 15) in association with an increased spare capacity of the serum for binding vitamin B,, (7,8,9,10,14). The importance of these findings as part of the pathophysiology of chronic myelocytic leukaemia has been debated.…”

mentioning

confidence: 99%

Studies on Free and Serum Protein‐bound Vitamin B₁₂ by the Use of Sephadex G 25 and High Voltage Electrophoresis¹

Lindstrand

Ståhlberg

Ehrensvärd

et al. 1963

Journal of Internal Medicine

View full text Add to dashboard Cite

Co⁶⁰ Vitamin B₁₂ Binding Capacity of Serum in Persons with Hematologic Disorders, Various Medical Diseases and Neoplasms

Cited by 27 publications

References 22 publications

Co⁵⁷ Vitamin B₁₂ Clearance Studies in Pernicious Anaemia

Co⁵⁷ Vitamin B₁₂ Clearance Studies in Pernicious Anaemia

Diagnostic and Therapeutic Perspectives Associated to Cobalamin-Dependent Metabolism and Transcobalamins’ Synthesis in Solid Cancers

Studies on Free and Serum Protein‐bound Vitamin B₁₂ by the Use of Sephadex G 25 and High Voltage Electrophoresis¹

Contact Info

Product

Resources

About

Co60 Vitamin B12 Binding Capacity of Serum in Persons with Hematologic Disorders, Various Medical Diseases and Neoplasms

Cited by 27 publications

References 22 publications

Co57 Vitamin B12 Clearance Studies in Pernicious Anaemia

Co57 Vitamin B12 Clearance Studies in Pernicious Anaemia

Diagnostic and Therapeutic Perspectives Associated to Cobalamin-Dependent Metabolism and Transcobalamins’ Synthesis in Solid Cancers

Studies on Free and Serum Protein‐bound Vitamin B12 by the Use of Sephadex G 25 and High Voltage Electrophoresis1

Contact Info

Product

Resources

About

Co⁶⁰ Vitamin B₁₂ Binding Capacity of Serum in Persons with Hematologic Disorders, Various Medical Diseases and Neoplasms

Co⁵⁷ Vitamin B₁₂ Clearance Studies in Pernicious Anaemia

Co⁵⁷ Vitamin B₁₂ Clearance Studies in Pernicious Anaemia

Studies on Free and Serum Protein‐bound Vitamin B₁₂ by the Use of Sephadex G 25 and High Voltage Electrophoresis¹